Steerable catheter unveiled to treat cardiac arrhythmia

Cambridge Design Partnership and King’s College London develop micro-moulded catheter which enables delivery of radio frequency energy to specific points in the heart tissue

Cambridge Design Partnership has worked with King’s College London to develop a steerable catheter to improve the treatment of cardiac arrhythmia.

The new steerable, micro-moulded catheter enables targeted delivery of radio frequency energy to specific points in the heart tissue for corrective treatment.

Compared with traditional catheters, the device has been designed to be quicker and easier to manoeuvre into the correct position, improving the accuracy of positioning and minimising damage to healthy tissue to improve success rates.

Cambridge Design Partnership won a four-way competitive bid to further develop the device created by King’s College London, involving helix-shaped interlocking tubes that would allow improved steerability and greater compatibility for robotic control over other catheters on the market.

The team at Cambridge Design Partnership successfully refined the initial design, enabling the device to meet key regulatory and biocompatibility requirements, while ensuring suitability for commercial manufacture.

Through CDP’s experience of developing highly-technical medical devices, the team was able to miniaturise the design to allow improved space for the delivery of ablation energy and irrigation.

The new catheter design is also assembled from micro injection moulded sections, incorporating features that enable it to be built on an automated assembly line at reduced manufacturing cost.

Matt Brady, head of medical therapy at Cambridge Design Partnership, said: “The steerable catheter is an extraordinary product, with innovative features that enable corrective treatment to be delivered to very specific areas of the heart.

“By enabling greater accuracy and quicker treatment time, we believe it is possible to preserve more healthy heart tissue, and increase the success of the treatment.

“It’s been hugely exciting to be involved in this joint project with King’s College London and use our expertise to bring such an innovative product one step closer to commercial use.”

Professor Kawal Rhode, professor of biomedical engineering at King’s College; London, added: “The team was chosen for the strength of its existing experience in developing catheters across both start-ups and global corporations.

“We were very pleased with the engineering approach and practical improvements they managed to incorporate. They delivered fully-moulded parts and specified other components and the assembly route which fully met our aspirations for the project.”

King’s College London is now undertaking extensive lab testing of the catheter device, with clinical trials expected to be take place in two to three years.